

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	General
Accord Healthcare (serplulimab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Asthma and Lung UK	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health - Northern Ireland
 Independent Cancer Patients Voice 	Healthcare Improvement Scotland
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary Care
Oncogene-Driven Lung Cancer	National Pharmacy Association
Patient Alliance UK	NHS Confederation
Roy Castle Lung Cancer Foundation	Scottish Medicines Consortium
Ruth Strauss Foundation	Welsh Government
South Asian Health Foundation	Welsh Health Specialised Services
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	
UK Lung Cancer Coalition	Comparator companies
	Accord Healthcare (cisplatin,
Healthcare professional groups	carboplatin, gemcitabine)
Association of Anaesthetists	AstraZeneca (durvalumab) Canadiant Llaghth (anthorita)
Association of Cancer Physicians	Consilient Health (carboplatin)
Association of Respiratory Nurse	 Hospira UK (cisplatin, carboplatin, gemcitabine)
Specialists	
Association of Surgeons of Great Britain and Iraland	,
Britain and Ireland	Sandoz (cisplatin)Sun Pharmaceuticals (gemcitabine)
British Institute of Padiology	Synchrony Pharma – part of CNX
British Institute of Radiology British Openlogy Pharmacy	Therapeutics (gemcitabine)
British Oncology Pharmacy Association	Therapeatios (geriotiabilie)
British Psychosocial Oncology Society	Relevant research groups
 British Psychosocial Officiogy Society British Society of Interventional 	Cochrane Lung Cancer Group
•	· ·
Radiology	Genomics England

Final stakeholder list for the evaluation of serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Thoracic Oncology Group British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care 	 Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
NHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

Issue date: November 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Consultee or commentator stakeholders are provisional until a CA&U form is signed at appraisal stage.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

Consultee or commentator stakeholders are provisional until a Confidentiality Agreement & Undertakings form is signed at appraisal stage.